| Literature DB >> 18350121 |
Keiichi Sakamoto1, Eiko Ohno-Okumura, Taku Kato, Masaki Watanabe, Michael J Cook.
Abstract
The phthalocyanine analogue containing nonperipheral longEntities:
Year: 2008 PMID: 18350121 PMCID: PMC2266814 DOI: 10.1155/2008/392090
Source DB: PubMed Journal: Met Based Drugs ISSN: 0793-0291
Figure 1Synthetic pathway of zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) porphyrazine.
Figure 3CVs of zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) porphyrazine.
UV-Vis and fluorescence spectral data of quaternized zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) porphyrazine.
| Compound | Q-band | Fluorescence | ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 687 | — | 694 | — |
| 2665 | — | — | — | |
| 2 | 1679, 650 | 1687, 647 | 692 | 688 |
| 1,2677, 2620 | ||||
| 3 | 1693, 658, 628, 597 | 708, 1687, 652 | 698 | 691 |
| 2673, 2645, 2605 | ||||
| 4 | 746, 1673, 649, 606 | 723, 1676, 646 | 683 | 688 |
| 2738, 1,2668, 2641, 2600 | ||||
1Main peak.
2In toluene.
Potentials of quaternized zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) porphyrazine in DMF with tetrabutylammonium perchlorate.Potentials of reversible wave are midpoint potential of anodic to cathodic peaks for each couple.
| Potential (V versus Ag/AgCl) | |||||||
|---|---|---|---|---|---|---|---|
| Compound | Reduction ( | Oxidation ( | |||||
| 1 | –0.94* | –0.62* | –0.29* | –0.03* | 0.32* | 0.48* | 0.97* |
| Δ | |||||||
| 2 | –0.75* | –0.52* | –0.12* | 0.96* | 1.28* | ||
| Δ | |||||||
| 3 | –0.83 | –0.51* | –0.05* | 0.25* | 1.05* | ||
| Δ | 0.14 | ||||||
| 4 | –1.15* | –0.77 | –0.14* | –0.05* | 0.50* | ||
| Δ | 0.11 | ||||||
* Irreversible peak.
**The anodic peak to cathodic peak separation for reversible couple.
Figure 4Fluorescence image of IU-002 cells. (a) Control and (b) Incubated with DMS quaternized zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido)porphyrazine and irradiated with halogen light for 10 minutes.
Figure 2Typical structures of quaternized zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) porphyrazines.